Future treatments for hereditary hemorrhagic telangiectasia
Abstract Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000–8000 individuals worldwide. This rare disease is characterized by various vascular defects including epistaxis, blood vessel dilations (telangiectasia) and art...
Main Authors: | Florian Robert, Agnès Desroches-Castan, Sabine Bailly, Sophie Dupuis-Girod, Jean-Jacques Feige |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-019-1281-4 |
Similar Items
-
Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management
by: Adrian Viteri-Noël, et al.
Published: (2022-09-01) -
Hereditary hemorrhagic telangiectasia and pregnancy: potential adverse events and pregnancy outcomes
by: Bari O, et al.
Published: (2017-05-01) -
Efficacy and Safety of Tacrolimus as Treatment for Bleeding Caused by Hereditary Hemorrhagic Telangiectasia: An Open-Label, Pilot Study
by: Josefien Hessels, et al.
Published: (2022-09-01) -
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial
by: Sophie Dupuis-Girod, et al.
Published: (2020-04-01) -
Bevacizumab as a treatment option in gastrointestinal bleeding associated to hereditary hemorrhagic telangiectasia. Case Report
by: Erwing Castillo, et al.
Published: (2019-07-01)